UroGen amends manufacturing pact for UGN-102; extends term to 2027, commits €4.4M for equipment

UroGen Pharma Ltd.

Amendment to manufacturing agreement with Cenexi extends initial term to April 1, 2027.
UroGen revised minimum annual quantity forecasts for bulk mitomycin purchases.
Company agreed to reimburse up to €4.4 million for dedicated capital equipment for UGN-102 production.
Amendment is in anticipation of potential approval and launch of UGN-102, a mitomycin product for low-grade upper tract urothelial cancer.
Parties will negotiate final terms on equipment purchase, installation, and validation.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

UroGen Pharma Ltd. amended Amendment No. 2 to Manufacturing & Supply Agreement with Cenexi-Laboratoires Thissen S.A. valued at approximately €4.4 million (effective 2023-12-28).

Action: amendment
Agreement: supply
Counterparty: Cenexi-Laboratoires Thissen S.A.
Value: approximately €4.4 million
Effective: 2023-12-28

Exact text from the filing

On December 28, 2023, UroGen Pharma Ltd. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to its Manufacturing & Supply Agreement with Cenexi-Laboratoires Thissen S.A. (“Cenexi”), dated as of April 24, 2020 and amended as of March 2, 2022 (as amended by the Amendment, the “Agreement”).

View on SEC.gov

Browse all material agreements →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-24-000244

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.